ARK Invest's position in BWAY, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| IZRL | 168,901 | $1.7M | 1.45% | #46 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-15 | IZRL | Buy | Added | 26,190 | $310K |
| 2026-07-16 | IZRL | Buy | Added | 5,981 | $89K |
| 2026-04-16 | IZRL | Sell | Trimmed | 51,186 | $785K |
| 2026-03-03 | IZRL | Buy | Added | 96,843 | $1.1M |
| 2026-01-15 | IZRL | Sell | Trimmed | 32,104 | $742K |
| 2025-10-16 | IZRL | Buy | Added | 113,500 | $1.8M |
| 2025-10-15 | IZRL | Buy | New position | 13,341 | $213K |
| 2025-07-21 | IZRL | Sell | Closed position | 0 | — |
| 2025-07-18 | IZRL | Sell | 25,037 | — | |
| 2025-07-17 | IZRL | Sell | Trimmed | 156,454 | $1.8M |
| 2025-07-16 | IZRL | Sell | Trimmed | 10,950 | $133K |
| 2025-04-22 | IZRL | Buy | Added | 4,564 | $38K |
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia,…
See BWAY's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open BWAY on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.